Follistatin-344's US Regulatory Status
What is Follistatin-344, and why does the name matter for its legal status
Follistatin-344 is a recombinant, truncated variant of the naturally occurring follistatin protein, engineered as a research compound to bind and neutralize myostatin (GDF-8) and related activin-family ligands. It is distinct from full-length follistatin-315 and from myostatin-targeting gene therapy constructs, both of which carry their own separate (and equally unapproved) status. If you see "follistatin" marketed without a form number, or paired with vague claims about "natural muscle growth," verify which molecule is actually being described before assuming any of the mechanistic literature applies. See our mechanism explainer and the 344 vs 315 comparison for how the variants diverge.
None of this changes the regulatory bottom line: no form of follistatin-344 has FDA approval for any use in humans.
Has the FDA approved Follistatin-344 for anything?
No. There is no FDA-approved drug product containing Follistatin-344, for bodybuilding, muscle wasting, injury recovery, or any other indication. It has never cleared a New Drug Application, and it is not marketed legally as a prescription or over-the-counter product in the United States. Any product sold as "Follistatin-344" for human use is being distributed outside FDA-approved channels, regardless of how it is labeled ("research use only" labeling does not create a legal pathway for human administration).
This is the single fact that governs everything else on this page. Claims of purity, sourcing, or "pharmaceutical grade" do not change approval status.
Is Follistatin-344 on the FDA's 503A bulk drug substances list?
No. Follistatin-344 is not included on the FDA's list of bulk drug substances that compounding pharmacies may use under Section 503A of the FD&C Act. That list is the mechanism the FDA uses to permit compounding pharmacies to prepare certain non-approved substances for individual patients under specific conditions. A substance's absence from the list does not automatically make compounding illegal in every circumstance, but it removes the clearest legal pathway a 503A pharmacy would otherwise rely on. You can review the list directly at the FDA's bulk drug substances page.
We are not making any claim here about Follistatin-344's FDA Category 2 nomination status, and readers should not infer one either way from its absence from the 503A list. Category 2 status and 503A bulk-list status are different FDA review tracks, and conflating them is a common source of confusion in this space. For a live, dated snapshot of where various peptides sit across FDA review tracks, use our FDA Peptide Status Tracker rather than relying on static claims that age quickly.
Does any country have Follistatin-344 approved?
We are not aware of, and are not claiming, foreign regulatory approval for Follistatin-344 in any jurisdiction. Readers researching international sourcing should not assume that a lack of a stated US restriction in a foreign marketplace implies that country's regulator has evaluated or approved the substance for human use.
Why hasn't Follistatin-344 gone through a normal approval process?
Approval requires sponsors to run controlled human trials demonstrating safety and efficacy for a defined indication, an expensive and multi-year undertaking that no company has publicly pursued for Follistatin-344 specifically. The preclinical literature on myostatin inhibition is real and reasonably active, but it is concentrated in animal models: mouse hypertrophy studies (PMID 34113826), porcine gene-editing work (PMID 34513293), dystrophic mouse models (PMID 31830002, PMID 33460149), and structural biology characterizing how related binding proteins neutralize GDF8/GDF11 (PMID 30814254). None of these are human Follistatin-344 trials. A closely related human data point comes from studies measuring myostatin biology in people after musculoskeletal injury or disease, such as quadriceps biomarker changes after ACL reconstruction (PMID 31817239) and serum myostatin as a severity marker in spinal muscular atrophy (PMID 38487549), but these describe endogenous myostatin biology, not administration of exogenous Follistatin-344. Long-term safety signals in animal models, including testicular abnormalities after chronic activin/myostatin attenuation (PMID 33408083), add reasons a sponsor would need extensive toxicology work before any human trial could plausibly proceed. For a fuller accounting of what the literature does and does not show, see our evidence quality review and muscle evidence summary.
Does the absence of human trials matter more than the paperwork gap?
Yes, and this is the point most sourcing guides skip. Even if Follistatin-344 were added to the 503A bulk list tomorrow, that would only affect the compounding pathway; it would not constitute evidence of safety or effectiveness in humans, and it would not change the fact that no controlled human trial has established a dose, an efficacy endpoint, or a safety profile for this specific molecule. Regulatory listing and clinical evidence are two separate questions, and a reader who confirms one should not assume the other follows.
A verification framework: don't let one "yes" answer three questions
When evaluating any claim about Follistatin-344's legal or clinical status, separate these three questions, because sellers routinely blur them together:
| Question | Current answer | What would change it |
|---|---|---|
| Is it FDA-approved for any use? | No | A completed NDA/BLA approval, which has not occurred |
| Can a 503A pharmacy legally compound it under the bulk-list pathway? | No, it is not on the list | FDA addition of Follistatin-344 to the 503A bulk substances list |
| Has efficacy or safety been established in human trials? | No published human trials exist in the sources reviewed here | Publication of a registered, peer-reviewed human trial |
A "yes" to one row never implies "yes" to another. If a seller cites one favorable-sounding fact (e.g., "research grade," "used in published studies," "not scheduled"), check which row it actually answers before treating it as reassurance about the other two.
What are the practical and safety implications of this gap?
Because there is no approved product, there is no FDA-reviewed dosing, no established injection protocol, and no verified manufacturing quality standard for material sold as Follistatin-344. Anyone considering it should understand that identity, purity, and dose accuracy of a given vial cannot be independently verified through any regulatory channel, and that adverse effects would not be captured by the standard postmarket surveillance systems that monitor approved drugs. Preclinical work also flags biologically plausible risk pathways worth taking seriously even in animal-only data, including effects on cardiac tissue relevant to myostatin signaling (PMID 38136649) and interactions with glucocorticoid and mTOR pathways relevant to muscle regulation (PMID 30805561). For a fuller risk discussion, see side effects and risks and dosing claims, which addresses why published human dosing does not exist to responsibly cite.
If you are recovering from injury, have a diagnosed muscle-wasting condition, or are managing a cardiac or endocrine condition, talk with your treating physician about evidence-based options before considering an unapproved research compound; urgent symptoms (chest pain, unexplained rapid muscle loss, severe injection-site reactions) warrant urgent medical evaluation, not self-directed peptide use.
What is established, what is plausible, and what is not established
Established: Follistatin-344 has no FDA approval, is absent from the 503A bulk list as of this writing, and has a substantial animal-model literature on myostatin inhibition and muscle hypertrophy mechanisms. Plausible but unproven: that myostatin-inhibition mechanisms demonstrated in mice, rats, and pigs would translate to a similar magnitude of effect, or an acceptable safety profile, in humans. Not established: any human efficacy data, human safety data, human dosing protocol, or regulatory approval anywhere, for Follistatin-344 specifically.
For where Follistatin-344 sits relative to other myostatin-pathway approaches and mainstream training interventions, see myostatin inhibitors landscape and follistatin vs. creatine.